CombiPlex®, Celator’s proprietary technology platform, introduces for the first time, the ability to collect in vitro drug combination informatics and apply those findings directly to the development of new clinically viable drug products.
This unique approach reflects several advantages:
1. The ability to identify drug combinations that exhibit ratio-dependent anti-tumor activity in vitro;
2. The opportunity to “lock” the synergistic ratio of drug agents in an effective drug delivery vehicle; and,
3. The ability to deliver and maintain the drug combination in vivo with the synergistic drug ratio consistently maintained.